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Abstract: Gamma-aminobutyric acid (GABA) is an important chemical compound in the human
brain. GABA acts as an inhibitory neurotransmitter by inducing hyperpolarization of cellular
membranes. Usually, this pharmaceutically important compound is synthesized using a chemical
process, but in this short overview we have only analysed microbial processes, which have been
studied for the biosynthesis of this commercially important compound. The content of this article
includes the following summarised information: the search for biological processes showed a number
of lactic acid bacteria and certain species of fungi, which could be effectively used for the production
of GABA. Strains found to possess GABA-producing pathways include Lactobacillus brevis CRL
1942, L. plantarum FNCC 260, Streptococcus salivarius subsp. thermophilus Y2, Bifidobacterium strains,
Monascus spp., and Rhizopus spp. Each of these strains required specific growth conditions. However,
several factors were common among these strains, such as the use of two main supplements in
their fermentation medium—monosodium glutamate and pyridoxal phosphate—and maintaining
an acidic pH. Optimization studies of GABA production were comprised of altering the media
constituents, modifying growth conditions, types of cultivation system, and genetic manipulation.
Some strains increased the production of GABA under anaerobic conditions. Genetic manipulation
focused on silencing some genes or overexpression of gadB and gadC. The conclusion, based on the
review of information available in published research, is that the targeted manipulation of selected
microorganisms, as well as the culture conditions for an optimised bioprocess, should be adopted
for an increased production of GABA to meet its increasing demand for food and pharmaceutical
applications.
Keywords: gamma-aminobutyric acid; microorganisms; monosodium-glutamate; biosynthesis;
immobilization; genetic-engineering
1. Introduction
Gamma(γ)-aminobutyric acid is considered as a major inhibitory neurotransmitter in
the central nervous system (CNS). The action of γ-aminobutyric acid (GABA) is specifically
reported in the brain cortex as a neurotransmitter of the CNS. Its key role is reducing
neuronal impulsiveness in the nervous system. It was an assumption, mentioned in several
reports, that GABA was unable to cross the blood–brain barrier, whereas some studies
did show GABA’s ability to cross the barrier. These studies were contradictory, and their
methods used in the assessment were not consistent. There has been some evidence in
support of GABA food supplements causing a desired calming effect, but again, these
were claims made by several consumers online [1]. GABA is an amino acid that is not
incorporated in proteins, and therefore, in most cases, it exists as a free amino acid. The
natural amino acids are α-amino acids, where the α-carbon, as the central chiral carbon,
contains a carboxyl group, a side chain, and an amino group; whereas, GABA is a non-α
amino acid due to its structure—the amine group is located away from the carboxylic acid
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end of the amino acid molecule. Therefore, GABA is not a canonical protein component, as
other α-amino acids are. GABA is a γ-amino acid with amine group bonded to the third
carbon, mentioned as the γ-position. Studies on this molecule demonstrated its main role
to counter the transmission of nervous impulses. Inhibition of neurotransmission is critical
in managing conditions of depression, anxiety, and stress.
Besides this, reduced concentration of the neurotransmitter in the brain has been also
correlated with Attention Deficit–Hyperactivity Disorder (ADHD) [2] and in neurological
irregularities, such as schizophrenia [3]. Other than these, several other pharmaceutical
properties of GABA have been reported on non-neuronal peripheral tissues and organs,
suitable for its application in cases of diabetes, hypertension, cancer, inflammation, allergy,
and in intestinal protection, hepatoprotection and renoprotection. Therefore, GABA has
been considered as an alternative potential therapeutic for the prevention and treatment
of numerous diseases [4–7]. The importance of this molecule in the human system has
stimulated the need to study its synthesis and its potential sources, which could be used to
manage disorders associated with its deficiency, e.g., functional foods, supplemented with
GABA. The types of GABA receptors, with their applications in food and pharmaceutical
industries, have been described in the following sections. The objective of this review is to
summarise the information available on the biosynthesis of this important compound in
an economical way, for a commercial scale use in food and pharmaceutical industries.
1.1. Types of GABA Receptors
Two types of GABA receptors have been identified and characterized—GABAA and
GABAB. Each of these receptors has different role in the central nervous system. GABAA is
an inotropic receptor, meaning that the binding of GABA alters ion channels, while GABAB
is a metabotropic receptor [3]. GABA, as an inhibitory neurotransmitter, causes hyperpolar-
ization of the membrane. Biologically, for a neural transmission to follow, the membrane
must be depolarized beyond its threshold. The depolarization stimulates an impulse that
is transmitted through the cell. Once it binds to any of the two receptors, chloride ions
flow into the cell, a situation that leads to hyperpolarization of the postsynaptic neuron.
The described mode of action is applied to manage various mental health problems [1].
GABA(C) receptors (Rs) are also worth consideration as a novel and significant target for
the pharmacological treatments of anxiety-related mental health issues, because it does not
desensitize, as other receptors GABA(A)Rs, and GABA(C)Rs are desensitized. This is the
reported reason that GABA(C)Rs and GABA(A)Rs work differently in the modulation of
associative plasticity in LA neurons of rats. GABA(C)Rs have extended the understand-
ing of GABA receptors in fear memory gain and its storage and, therefore, it has been
recommended as a possible novel target for the treatment of disorders of anxiety and
fear [6].
1.2. Properties and Applications of GABA
GABA helps in increasing protein synthesis, increasing the production of growth
hormones, and reducing the risk of lungs adenocarcinoma. It is reported to be an effective
tumour suppressor for small airway-resulting lung adenocarcinoma [7]; research outcomes
have suggested that marker-guided action of GABA, or a GABA(B)R, could be a novel
targeted approach for the prevention of pulmonary adenocarcinoma in smokers. GABA
has been suggested as an inhibitor in nicotine-imposed stimulatory challenge of non-small
cell lung carcinoma in xenograft models [8,9]. GABA is an amino acid that has established
its applications in both the food and pharmaceutical industries [10,11]. In addition, GABA
has been reported showing antidiabetic, hypotensive, and diuretic effects [1,2,12]. As a
neurotransmitter, it helps in improving memory, pain moderation, and regulation of lipids
levels in the body. Other researchers have also reported that GABA helps in improving
metabolism [12]. Currently, food manufacturers have been adding its small amounts to
food preparations, such as shochu, cheese, gammalone, and gabaranone tea [11].
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With the increased understanding of the importance of GABA in neuroprotection,
asthma, and immunological disorder, the demand for food fortified with this compound
has increased and some commercial GABA products (Table 1) are already available in
market as supplements.
Table 1. Commercial GABA Products Available in Market **.





Now supplements 500 mg capsules not known Vitamin Angels
Double Wood
Supplements 1000 mg capsules not known
Double Wood
Supplements
Natural source GABA Gelatin capsules not known Pure OrganicIngredients
Horbäach GABA 500–1000 mgcapsules not known Horbäach
GABA calm Tablet not known Source Naturals







** Information sourced from: https://www.amazon.com/gaba/s?k=gaba (accessed on 26 November 2021).
2. Processes of GABA Production
Methods used for GABA production could be chemical or biological processes. The
main factor determining a suitable method is the overall economics of the production,
which count towards the cost of production and the net output yield that is achieved in
selected process. For a commercially viable process, the most economically favourable
method of synthesis should be used.
2.1. Bioprocesses
In recent years, several reports have been published on the production of medically
important GABA using selected microorganisms as effective biocatalysts. Although mi-
croorganisms are mostly known for causing diseases and affecting the overall life of human
beings, in extensive research, several of them have been identified as non-pathogenic. The
GRAS (generally regarded as safe) microorganisms are currently used in the production
of various industrially and medically important compounds. The opening of advanced
molecular and biotechnology techniques has helped in understanding the growth and
metabolism characteristics of selected microorganisms. Besides this, new techniques are
currently used to modify the genetic makeup of desired microorganisms to optimize the
production of selected secondary metabolites. GABA is one of such metabolites that can be
effectively produced by microorganisms [10].
The advantage of using microorganisms in the biosynthesis of an added-value com-
pound is that they could be easily manipulated, and the process could be optimized for the
purpose. Therefore, several biological processes employing microorganisms in fermenta-
tion systems have been studied for the synthesis of added-value secondary metabolites. A
large number of microbial metabolites are utilized in healthcare as antimicrobial, antipar-
asitic, antitumour, and immunosuppressive agents [13,14]. Few species of microbes are
known to produce useful metabolites for the food and fermented beverages industry, these
strains could be easily managed diverting them for the biochemistry of GABA synthesis.
Due to the deployment of selected microorganisms in the synthesis of this useful com-
pound, there is a need to evaluate their cultivation in fermentation systems and optimize
those factors affecting its biosynthesis in culture medium. The aim of such studies has been
to establish an optimized cost-effective bioprocess for the production of GABA [10].
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The study on the production of microbial metabolites has opened up avenues for the
modification of respective microorganisms for optimal production. Therefore, to achieve
improved yield of a desired secondary metabolite, growth conditions of microbes may
be manipulated to prolong the stationary phase in the culture’s growth cycle. Similar
approaches can also be applied for GABA production through microbial fermentation
with the support of an inducer monosodium glutamate (MSG) [15]. The selected form of
GABA, either natural or synthetic, showed the tendency of receptor binding, and produced
effects of inhibition of stress signals and decreases in sleep latency [16]. These outcomes
emphasized the need for finding specific microbial strains and studying their capability
for biosynthesis of GABA. For this purpose, specific groups of strains were first screened
for their ability to produce this molecule, then their physiological requirements were
studied for their optimal growth [17]. The characterization of potential microorganisms
was followed by the proposition of an optimized biosynthesis process, for cost-effective,
commercial-scale production.
2.2. Strategies for Biosynthesis
When comparing the two methods, microbial production seems to be more promising
than chemical synthesis, due to the high biocatalytic efficiency of selected microbial strains.
Microbial production of GABA has been studied for optimization of culture conditions
needed by specific strains, primarily with relation to growth temperatures, and the time
phase of compound appearance in culture medium [17–19]. In a biosynthesis production
process, a non-essential amino acid glutamate is readily decarboxylated to GABA, catalysed
by an enzyme glutamate decarboxylase (GAD), EC 4.1.1.15, as shown below Figure 1:
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and pyridoxal phosphate (PLP) is used as a cofactor for the activity of GAD. The molecular 
reaction is summarised as follows: 
HOOC-CH2-CH2-CH(NH2)-COOH → HOOC-CH2-CH2-CH2NH2 + CO2 (1)
GAD in mammals exists in two isoforms with molecular weights of 67 and 65 kDa, 
reported as GAD67 and GAD65, which are encoded by two different genes on different 
chromosomes GAD1 and GAD2 genes. 
Few fermentation methods for the bioproduction have been tested and proposed [20–
25]. Some of these have reported the use of immobilized microbial cells, batch fermenta-
tion, and sourdough fermentation. The immobilized cell method is a technique mostly 
applied in situations where excessive free cell mass can have an adverse effect on the pro-
duction of the required metabolite. Therefore, the microbial cells are immobilized to pre-
vent surplus cell division, channelizing the energy from carbon source for the production 
of metabolite [18–20]. 
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Figure 1. The biosynthesis production process, a non-essential amino acid glutamate is readily
decarboxylated to GABA, catalysed by an enzyme glutamate decarboxylase (GAD), EC 4.1.1.15.
GAD enzyme is responsible for the decarboxylation of glutamate to GABA and CO2,
and pyridoxal phosphate (PLP) is used as a cofactor for the activity of GAD. The molecular
reaction is summarised as follows:
HOOC-CH2-CH2-CH(NH2)-COOH→ HOOC-CH2-CH2-CH2NH2 + CO2 (1)
GAD in mmals exists in tw isoforms with molecular weights of 67 and 65 kDa,
r ported as GAD67 and GAD65, which are encoded by two differ t ge es on different
chr o omes GAD1 and GAD2 genes.
Few fermentation meth ds for the bioproduction have been t sted and pr posed [20–25].
Some of these have reported the use of i mob lized microbial cells, batch fermentation,
fer entation. The immobilized cell method is a technique mostly applied
in situations where excessive free c ll mass can have an adverse ffect on the production
f the r quired metabolite. Therefore, t e i r i l ll are immobilized to prevent
surplus cell division, cha nelizing the energy from carbon source for the production of
metabolite [18–20].
Besides the changes in microbial-cultivation methods, the modifications in the energy
sources used for the growth of microbes in fermentation medium were also studied. The
productivity of a metabolite could be altered, when wheat flour, a carbon source, was
replaced by amaranth and quinoa flours [26]. Varying carbon sources is an effective
technique to maximize the yield of a metabolite in the production line. The strains could
be acclimatised to metabolize readily available carbon sources as low-cost raw materials
for economical production [17,18].
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The changes noted in the production of GABA, by reducing the cost of process and
increasing the yield, are encouraged by the increasing demand for this compound in food
and pharmaceutical industries.
3. Selected Microbial Strains
Manufacturers seek to identify the best methods to improve production to maximize
their profits. Therefore, some strains of microorganisms used in the food industry have
also been studied for their effectiveness in GABA production. The modification in mi-
croorganisms’ metabolic pathways directs the energy towards the production of the target
compound. The stationary phase in the microbial fermentation process is characterized
by the accumulation of secondary metabolite, which could be toxic to microorganism.
The toxicity stimulates the onset of death phase, where some modifications in culture
parameters, such as pH and temperature, can help the microorganism build tolerance
for metabolites produced in fermentation. Modified growth environments of incubation
under anaerobic condition have been successful in producing a higher yield of GABA in
fermented products by fungal cultures [27]. A new source of GAD to produce high yields
of GABA has been studied in engineered microorganisms, like Escherichia coli [28].
Concise information on specifically selected GABA-producing strains is discussed in
following sections.
3.1. Lactic Acid Bacteria
3.1.1. Production and Factors
Studies have been performed to test the ability of specific strains of lactic acid bacteria
(LAB) to produce GABA. Two LABs, selected for their capability to produce a significant
amount of metabolite, were Lactobacillus brevis CRL 1942 [18] and L. brevis GABA 057 [20].
Among these, L. brevis CRL 1942 was reported to be more efficient in production. During the
fermentation process, LAB strains were provided with suitable carbon sources in medium
and supplemented with MSG, a commercially available product, mostly used in the food
industry. Results indicated a significant concentration of GABA produced in L. brevis CRL
1942 within a short period of fermentation (50 mM in 96 h). The process parameters opti-
mized for this LAB included MRS broth, quinoa, and MSG, and the incubation temperature
of fermentation was set at 30 ◦C [18]. This study demonstrated that the microbial synthesis
could be more cost effective after the optimization procedures were applied.
3.1.2. Optimization
The first factor that should be considered during the GABA bioprocess is the con-
centration of MSG added in the fermentation culture. The researchers focusing on the
production of GABA using L. plantarum FNCC 260 noted that increasing concentration
of MSG in the culture broth switched to a significant increase in production [25]. MSG
is a source of glutamate that was required as a precursor by the microorganism for the
efficient production of GABA. The basic mechanism behind the increased production with
increased MSG concentration was the induction of GAD enzyme production. Therefore,
increasing the concentration of MSG increased the production of GAD, which was required
for converting glutamate to GABA [28]. However, the concentration of the added MSG
needed to be closely monitored. The concentration of MSG at 270 mM was found suitable
to induce maximum biosynthesis. Increasing the concentration beyond this level increased
the osmotic pressure and thus reduced the production of GABA.
Temperature was also an important physiological factor that needed monitoring to op-
timize the production. The study, using L. brevis CRL 1942, demonstrated high production
of GABA at 30 ◦C. The report concluded that 22, 25, and 37 ◦C were unsuitable of for the
production process. The conclusion on the right temperature to optimize production was
credited to its effect on activity of GAD enzyme. The time factor also needs to be considered
for optimal consumption of MSG—the study on L. brevis CRL 1942 demonstrated that its
conversion rate was highest (90%) at 48 h of culture. The change in production rate was
Microorganisms 2021, 9, 2457 6 of 16
linked to changes in pH, caused by the release of hydrogen ions after decarboxylation of
MSG to GABA. The higher concentration of hydrogen ions in medium caused a drop in
pH, which could have affected the activity of GAD enzyme [18].
3.2. Lactobacillus Plantarum
3.2.1. Production and Factors
Studies on Indonesian foods—tape ubi, gatot, growol, and bekasam—confirmed them
to contain significant numbers of Lactobacillus species, which could be used to produce
considerable amounts of GABA. With such a possibility, researchers isolated active strains
from fermented food to study their ability to produce this compound. In the screening
process, 30 Lactobacillus strains were isolated from above mentioned fermented foods [25].
These isolates were cultured in MRS broth at 37 ◦C for 24–48 h. MSG was added at a
concentration of 118 mM in the growth medium, and a micro-aerophilic condition was
maintained during the incubation of the cultures. The synthesis of GABA was detected
for its presence in the culture filtrate, obtained from respective Lactobacillus species, and
compared with pure form of a commercial GABA as a standard, using a method of thin
layer chromatography. The best producer strains were identified by 16S rDNA sequencing
and proteomic identification, using MALDI-TOF MS techniques. [25].
The identified isolates were further studied and two strains producing a significant
amount of GABA were finally selected for GABA synthesis. Lactobacillus plantarum FNCC
260 and L. plantarum FNCC 434, under optimized conditions, produced an average of
352 mg/L and 328 mg/L of GABA, respectively. The synthesis timeline for maximum
production of GABA was studied, the results obtained stated that the production started
after 12 h of culturing of Lactobacillus strains, which was related to the start of cultures’
stationary phase. The synthesis of GABA increased after 48 h, and yield reached maximum
after 60 h (809.2 mg/L) [25]. After this time, the concentration of GABA in culture started
weakening. This decline was associated with production of enzyme GABA–transaminase
(GABA–T E.C.2.6.1.19.), which catalysed the degradation of GABA molecule. The study
suggested that genetic modification of the strains could help to reduce GABA–T production
and thus the production of GABA could be prolonged from L. plantarum FNCC 260 strain.
Similar to other studies conducted with L. brevis strain [18,20], researchers also noticed
a significant drop in pH during GABA production in L.plantarum. Within first 12 h, the
pH dropped from 6.5 to 4.1. Unlike in L. brevis, where the drop in pH was recognized due
to increased production of hydrogen ions in the decarboxylation process, in this case, the
formation of acetic and lactic acid caused the drop in pH. It was also noted that despite
the expression of GABA–T after 60 h of fermentation, the pH of the medium continued to
decrease until 84 h, suggesting GAD was also active and GABA production was continuing.
3.2.2. Optimization
Cofactors are essential molecules that help in the catalytic process. Therefore, various
enzymes require certain cofactors to improve their efficiency. Addition of PLP in the
medium has been reported to increase GAD activity, and subsequently, the production
of GABA. In this case, adding 0.2 mM of PLP increased production to 903.0 mg/L, while
0.6 mM PLP increased the yield to about 945.3 mg/L [25]. These values were obtained after
the cultivation of strains for 108 h.
Another interesting characteristic was noted that the production time was prolonged
after the addition of PLP. In medium without supplementation of PLP, GABA production
declined after 72 h; while in the presence of cofactor, the production was extended to
108 h. This finding was also supported by other studies performed using different GABA-
producing strains. The addition of 0.1 mM pyridoxine also led to a significant increase
in GABA production; therefore, this cofactor can also be used as an alternative additive
to the culture media. The advantage of these cofactors is that they do not affect biomass
production. The results suggested that the addition of the right amount of PLP could boost
the production of GABA on larger scale [23].
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The presence of MSG in medium was also noticed to be essential for microbial produc-
tion of GABA using L. plantarum FNCC 260. The addition of 10 mM of MSG to L. plantarum
culture medium increased production to 1226 mg/L after 96 h of fermentation. Beyond this
time, glutamate production declined due to the expression of GABA–T, which synthesized
succinic semi-aldehyde (SSA) from GABA [26]. Excess addition of MSG caused a decline
in the production of GABA. The main reason for the decline was the toxic effect of higher
levels of MSG on LAB strains. A higher concentration of MSG induced its toxic effect by
suppressing gad B genes, which code for GAD [25].
Recombinant techniques were also applied to maximize production. The recombina-
tion increased the effectiveness of a bacterial strain, by improving its tolerance to acidic pH,
caused by production of acetic and lactic acid, and the release of hydrogen ions. The genetic
modification of the strain also reduced fermentation time. In a study, the recombinant
L. plantarum FNCC 260 strain produced about 6450 mg/L of GABA within first 6 h. Besides
this, the GAD activity was also above 73% after 6 h, which suggested the possible cause of
higher yield [25] by the recombinant strain. The genetically modified strains are reported
to reduce the production of GABA–T and other GABA-degrading enzymes. Therefore,
genetic engineering can be an effective tool for increasing the production of GABA by
several folds, through reducing the degradation of product, increasing the resistance for
acidic pH, and shortening the production time. In one of such efforts, reverse genetics
mechanism was used to identify the role of GABA metabolism in Stagonospora nodorum [29].
Recombinant techniques were also used to improve the synthesis in a process employing
C. glutamicum [30].
3.3. Streptococcus salivarius
3.3.1. Production and Factors
The fermentation process was conducted, cultivating Streptococcus salivarius in a
nutrient medium supplemented with peptone, beef extract, MSG, dibasic ammonium
citrate, and other compounds. The production of GABA was improved by adjusting the
pH after every 12 h using sodium hydroxide. The study showed that the intracellular
concentration reached its maximum at 24 h, and the extracellular concentration was highest
at 84 h. The production of GABA increased after the pH of the medium dropped to about
4.5–5.0, and a significant production of GABA was detected even after cell death [21].
3.3.2. Optimization
A study assessed the favourable conditions for GABA production in S. salivarius subsp.
thermophilus Y2, as the optimum temperature in range of 40–45 ◦C and pH 4.5; although, the
optimum temperature for GAD was 34–37 ◦C, and its activity was significantly inhibited
above 46 ◦C [21]. The researchers suggested a need to maintain the conditions within
these ranges to improve production. This study also reported that the addition of MSG
significantly increased GABA production by S. salivarius, though the excessive addition
caused significant toxicity. In addition to this, PLP also stimulated the production of GABA.
Although the yield from S. salivarius subsp. thermophilus Y2 was significantly high, it
was lower compared to the amount produced by other lactic acid bacteria. A strain of
Streptococcus thermophilus produced higher concentrations of GABA in fermented milk,
highlighting a natural production method for functional food [22].
3.4. Bifidobacterium and Lactobacillus Strains
3.4.1. Production and Conditions
Although GABA production has been assessed using bacteria, mostly isolated from
fermented food materials, production by bacteria isolated from gastrointestinal tract had
not been examined. In the study, the researchers obtained 135 bacterial strains of Lactobacil-
lus and Bifidobacterium. These bacteria were isolated from samples of saliva and faeces of
volunteers and cultured in MRS with 10% carbon dioxide, and the incubation temperature
was maintained at 37 ◦C for 24–48 h. Bifidobacterium strains required MRS medium supple-
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mented with 1% MSG, 0.05% cysteine, and a suitable carbon source. When provided with
a sufficient level of MSG, 24 strains of the Bifidobacterium and 111 Lactobacillus produced
significant amounts of GABA [23].
Lactobacillus species were identified as plantarum and brevis, confirming initial re-
ports of other researchers. Bifidobacterium strains included B. dentium, B. angulantum, and
B. adololescentis. Comparing efficiency, the average production in all strains was between
50–6000 mg/L. L. brevis produced higher yield (679 mg/L), compared with L. plantarum
strains, with an average production of about 300 mg/L. Bifidobacterium strains were better
producers (an average of 2500–6000 mg/L of GABA) than the Lactobacillus strains [23]. The
research demonstrated that Bifidobacterium strains could be employed for the industrial
production of GABA. Furthermore, studies on GAD genes and their role in altering the
production and the role of MSG as a precursor will allow the establishment of the optimum
culture conditions needed for an economical commercial yield [28].
3.4.2. Optimization
The manipulation of growth conditions optimized the shortest production time; where
Lactobacillus strains produced the maximum amount of GABA after 72 h, and Bifidobacterium
strains produced the maximum amount of GABA after 48 h [23]. The differences were
associated with the different onset of stationary phases in growth cycle of both strains. In
addition, PLP also had varying effects on bacterial strains. It was initially reported that the
addition of PLP at the initial stages of fermentation had no significant impact on GABA
production. However, adding this cofactor at the late stages of fermentation (after 72 h)
led to improved production. The reason behind this increase was the late expression of
the gadB gene, and the high degree of degradation of PLP during the lag and log phases of
bacterial growth. For maximized production, it is important to use a fermentation method
that will allow the addition of cofactor at the later stages of bacterial growth.
The cloning of genes from different strains through co-expression of GAD, derived
from Lactobacillus brevis, also enhanced the production [30]. This approach minimized the
degradation of PLP during the growth cycle of cultures. Bifidobacterium strains showed
stable production of GABA due to the capacity of these strains to synthesize vitamin B6.
Bifidobacterium strain can be genetically manipulated to overexpress the gadB and gadC
genes and increase the expression of vitamin B6 synthesizing genes.
3.5. Monascus spp. and Rhizopus spp.
3.5.1. Production and Factors
A few non-bacterial strains have also shown capability to produce significant amounts
of GABA, one such reported organism is Monascus sanguineus [24]. The factors required to
synthesize GABA by this mould were potato dextrose agar, magnesium sulphate, peptone,
and incubation at temperature of 30 ◦C. The process time required for its cultivation was a
minimum of one week under solid-state fermentation condition. Another species of fungi,
Monascus purpureus CCRC 31615, was also found to produce GABA. The production of
GABA compound was confirmed using chromatographic techniques.
A number of Rhizopus spp have been studied for biosynthesis of GABA under suit-
able conditions provided for fungal cultivation. One study assessed the effectiveness of
R. oligosporus when it was grown using quinoa as a substrate, results demonstrated that
the fungus produced up to 540 mg per kg of substrate used after 5 days of growth [26]. In
addition, the production of significant amounts of vanillin acid, Gallic acid, and L-carnitine
were also noted. A study using R. Microsporus var. oligosporus IFO 8631 reported that
this strain could produce maximum amounts of GABA when fermented soybeans were
added to the production medium. The duration of anaerobic and aerobic conditions in the
fermentation process could also significantly affect the synthesis of GABA [27].
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3.5.2. Optimization
Techniques applied to optimize production of GABA by Monascus spp included the
modification of growth conditions, substrate addition, growth time, and genetic manip-
ulation. However, the production was also found to be dependent on the duration of
fermentation. Maximum production by fungal cultures with 0.5% MSG addition was
reported after 20 days [24]. Maintaining the right level of pH was also essential for maxi-
mizing the production of GABA by Monascus spp. Monascus sanguineus performed better
with maintaining the pH of cultivation medium at 5.5. Furthermore, the wheat powder
was the preferred carbon source by fungal cultures than the other substrates used, such
as rice and sweet potato starch. A study on M. purpureus CCRC 31615 showed that ad-
dition of sodium nitrate increased GABA production to 1267.6 mg per kg of substrate
used. Furthermore, the yield increased to 1493.6 mg/kg after the addition of dipotassium
hydro phosphate. Improved production by Rhizopus spp. was achieved with implemen-
tation of optimized conditions of cultivation time, a suitable carbon source, and growth
conditions [29].
4. Main Outcomes of Studied Bioprocesses
4.1. Requirements for Biosynthesis
The comparative study on processes employing bacterial and fungal strains showed
that each microbial culture required its own specific factors to produce GABA. However,
there were certain factors that were common among all microbes tested. Among these, the
common factors were the supplementation of PLP and MSG, which are the same factors
that have been reported in the study of GABA production employing L. plantarum FNCC
260 [25]. MSG acted as a precursor substrate, while PLP is a cofactor, required by enzyme
GAD. The fermentation time varied between different strains. On average, most bacterial
strains produced satisfactory amounts of GABA after 72 h. Others were able to prolong
production time to more than 108 h, when optimized conditions were introduced to extend
the stationary phase of GABA synthesis. Fungal strains required suitable solid particulate
substrates as carbon sources for their mycelial cultivation under a solid state, along with
both supplements of MSG and PLP. A fungal strain Rhizosporus microsporus var. oligosporus
IFO 8631 was more effective under anaerobic conditions for GABA synthesis [27]. Therefore,
the production of GABA using any of the strains would require a detailed study on their
physiology and the GABA synthesis phase in their growth cycle.
4.2. Manipulations of Microbes
The analysis of studies conducted using various GABA-producing microorganisms
revealed that strains could be manipulated to obtain better yield of this molecule. Some of
the microorganisms were also genetically modified for the purpose [19]. Genetic engineer-
ing helped in improving production, boosting tolerance, and reducing the virulence under
toxic conditions. One of the methods used in altering the genetic sequence of strains was
to either activate or shut down specific pathways. The process can be performed either by
the deletion or the silencing of respective genes, using this strategy, the performance of
Stagonospora nodorum could be improved through its genetic modification [29]. The main
objective of this molecular technique was to enable the microorganism to gain specific
characteristics that would help increase GABA production. The maintenance of an acidic
pH in fermentation medium was identified as a method of optimizing production, in all
GABA producers [25–31]. The addition of PLP and MSG at their specific concentrations
was also essential in boosting GABA production. Besides some common factors, microbial
strains, specifically selected for GABA synthesis, might require additional requirements
and modifications, which would be unique to each strain of bacteria or fungi for achieving
maximum yield of GABA [32–37].
Studies on GAD genes have also been performed to assess their role in altering the
production of GABA in different strains. An interesting study reported that the usage
of recombinant GAD modified from L. plantarum FNCC 260, with expression through
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Escherichia coli, triggered a GABA yield 5-fold higher than that which was obtained in the
fermentation process with the usual LAB process [19].
On sequencing the genes of the GABA-producing strains, the researchers identified
that most of the strains expressed the gadB gene after the provision of sufficient measures
of MSG. However, the mutations on the gadB gene in nine strains of L. fermentum was also
noted, which explained why these strains did not synthesize any GABA, despite having the
gadB gene. Other studies have also reported that mutations might have affected the produc-
tion of GABA in several bacterial strains. Besides this, decreased compound production has
also been linked with deletion or mutation of the gadC gene. The gene encodes for an an-
tiporter that exports GABA out of the cells. Excessive accumulation of the compound inside
the microbial cell could have a negative impact on the biosynthetic pathway [28]. Reverse
genetics is also applied to manipulate microorganisms for maximum production. An exam-
ple of reverse genetics is applied in creating genetic mutants lacking the Sdh1 gene that is
required for succinic semialdehyde dehydrogenase production. That was confirmed by in-
serting this gene, which led to increased production of GABA by Stagonospora nodorum [29].
Such possibilities have further enhanced its significance as a commercial compound, which
could be produced by microbes as a secondary metabolite. With the extensive information
available as discussed above, GABA production could be developed for use in several
industries, including nutraceuticals, food, and pharmaceutical [38–41].
4.3. Effective Strategies
The immobilization and multilayer co-encapsulation techniques for effective employ-
ment of selected microbes have been established for enhanced biosynthesis of GABA,
through their use in multi-cycle processes [40–42]. In a study, an immobilized form of
enzyme GAD was used for the biosynthesis of GABA, for immobilization first this enzyme
was synthesized in fermentation process growing a LAB (L. plantarum) in the rice vinegar
and MSG medium [43]. The GadB gene encoding GAD from L. plantarum was expressed in
Lactococcus lactis. The characterization studies confirmed that the recombinant GadB was
a homodimer, and its maximal performance was achieved at pH 5.0 and at its optimum
temperature of 40 ◦C. The elevated production of GABA has been reported using an immo-
bilized form of GAD. The support material for immobilization used for the immobilization
of enzyme was a porous material—a hybrid of organic–inorganic amphiphilic [44].
The effective strategies enhancing GABA biosynthesis by specifically selected micro-
bial strains should be tried for obtaining better yields, such as those in molecular cloning,
expression and immobilization of GAD [45], and physiology-oriented engineering [46].
GAD system is highly unpredictable in different strains, as some species have one, two,
or three GADs followed by antiporters either none or one, sometimes even two. For
example, Mycobacterium tuberculosis has been reported to have a GAD gene without an
antiporter [47]; however, Listeria monocytogenes has been reported to have three GADs and
two antiporters [48]. Therefore, the properties of GAD at chemical and physical levels
differentiate considerably in quite a few strains, hence, new GAD enzymes are continuously
searched for, with a possibility of finding one with a higher biotechnological significance.
GAD gene sequence detected in different microorganisms also can suggest its capability
to produce GABA at genetic level [49,50]. In such approaches, Lactococcus lactis has been
studied for improved output of a biosynthetic process [51].
Two isozymes of GAD have been studied in Lactobacillus brevis for their contribution
in GABA synthesis, by providing resistance to acid formed in fermentation medium [52].
Some researchers have preferred to use those microbial strains for GABA biosynthesis,
which were isolated from food sources such as cheese, sourdough, and fruits [53]. In
the fermentation process, MSG, a GABA-precursor, was replaced by plant sources, such
as fenugreek seeds and soybean, or an animal source such as gelatine, which contained
glutamic acid or glutamine. In order to control similar amounts of either precursor in
all fermentation batches, the amount of plant or animal sources containing the same
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concentrations of glutamine and glutamic acid as those in control MSG-supplemented
experiments, were used [53].
The demand in several countries for foods enriched with GABA has increased to obtain
the benefit of the physiological functions of this compound. However, some researchers
have contradicted the direct addition of this compound to food items, stating their concern
on this practice being unnatural and unsafe [54]. Therefore, alternative applications of
GABA, other than as a food supplement, should be explored for medicinal purposes, such
as in wound healing [55].
In this overview article, it is not possible to discuss all bioprocesses, therefore Table 2
has summarized some of the microorganisms selected to perform as biocatalysts in GABA
production and their essential factors applied in the biosynthesis process. The references
included in Table 2 have emphasis on certain requirements, which could be used and
maintained during fermentation cycle to enhance the yield of GABA in microbial synthesis
processes. The studies have also used supplementations, including inorganic nitrogen
sources such as ammonium salts, organic sources such as peptone, casein, and beef ex-
tract, NaCl, initial MSG concentration, required amount of GAD-cofactor PLP, etc. The
results concluded that the selection of ingredients, constituting a fermentation medium,
with specifically selected sources of carbon, nitrogen, and other components should be
optimised for improved yield of GABA. Using such an approach, L. lactis was cultivated in
a nutritional medium using a mixture of three carbon–nitrogen sources at a ratio of 33:58:9,
including brown rice juice, germinated soybean juice, and enzymolyzed skim milk, which
produced a good yield of up to 6.4 g/L [56].
Table 2. Selected Microbial Systems and Their Requirements for the Synthesis of GABA.
Microorganisms Employed
in Bioprocess Yield of GABA, or Product Requirements Reference
Lactobacillus brevis CRL 1942,
an isolate from quinoa
sourdough





23.6 g/L at 36 h in batch fermentation
31.3 g/L at 57 h in fed batch fermentation
Engineered MSG pathway
3 genes gadA, gadB, gadC cloned [19]
L. brevis GABA 057 by
gel-entrapment of bacterial
cells
223 mM after 48 h of fermentation
534 mM MSG;
addition of iso-malto oligosaccharide to
alginate beads, 34 ◦C, pH 4.2
[20]
S. salivarius subsp.
thermophilus Y2 7984.75 ± 293.33 mg/L at 48 h
PLP 0.02 mmol/L
Peptone, beef extract, MSG, ammonium
citrate, 40–45 ◦C, pH 4.5–5.0
[21]
Streptococcus thermophilus,
co-culture with L. rhamnosus
production of fermented milk
enriched with GABA
5.4 g/L;
8.3 g/L when co-cultured with L.
rhamnosus;
1 g/L skim milk powder, or yeast
extract or soy protein hydrolysate






L. brevis 675 mg/L,
L. plantarum 300 mg/L
Bifidobacteria 2500–6000 mg/L
MRS, 1% MSG, 0.05% cysteine. 37 ◦C




a fungal species belonging to
family Elaphomycetaceae
15.53 mg/gm dry substrate (20 days
solid-state fermentation).
Wheat powder, potato dextrose,
magnesium sulfate, peptone, 30 ◦C.
MSG 0.5%, pH-5.5
[24]
L. plantarum FNCC 260,
isolates of Indonesian
fermented foods
945.3 mg/L at 108 h MSG, MRS medium0.1 mM PLP, 37 ◦C, pH 4.1 [25]
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Table 2. Cont.
Microorganisms Employed
in Bioprocess Yield of GABA, or Product Requirements Reference
Rhizopus oligosporus
540 mg/kg (50 h)
in fermented foods by solid-state
fermentation
Quinoa, soybeans
pH-5.5, PLP, MSG-0.5% [26,27]
Escherichia coli
genetically engineered with
StGAD, SsGAD, and ScGAD
used as whole-cell biocatalysts
2.771 kg/L with average molar
conversion rate of 67% in 20 h by
glutamate decarboxylation of
MSG/L-glutamic acid
GAD from Streptomyces; engineered





co-expression of 2 LAB-genes
22.57 ± 1.24–30.18 ± 1.33 g L−1
36 h
gadB1 and gadB2 from L. brevis;
urea supplementation [30]
Streptococcus thermophilus
APC151, isolate of fish
digestive tract
Bioactive yogurt enriched with 2 mg/mL
GABA produced in fermentation
14% (w/v) skim milk; 2.25 mg/mL
MSG; 42 ◦C for 48 h [31]
L. Plantarum Taj-Apis 362
overexpression
11.09 mM in 60 h;
predicted value 11.23 mM by response
surface methodology
GAD enzyme; 497.973 mM glutamic
acid, 36 ◦C, pH 5.31 [37]
L. plantarum EJ2014 19.8 g/L159.7% of theoretical maximum yield
100 g/L yeast extract, 10 g/L glucose,
2.25% MSG [39]
Probiotic bacterial strains Development of functional food products Co-encapsulation of bacterial cells withbioactive compound in a single matrix [40]
Lactic acid bacteria
Microcapsules of LAB and GABA for
targeted intestinal delivery in functional
food formulations









containing GABA, probiotics, and
prebiotics
Matrix of exo-polysaccharides dextran,
inulin, maltodextrin [42]
L.s plantarum Rice vinegar MSG with food-grade
γ-aminobutyric acid
Immobilized enzyme GAD from L.
plantarum [43]




Yield 5.15 g/L; productivity 3.09 g/L per
hour
by immobilized enzyme for 10 repeated
uses
GAD molecular cloning, expression,
immobilization [45]
gadA, gadB, gadC, gadCB,
gadCA from L. brevis cloned
into pMG36e
43.65 g/L at 98.42% GABA conversion
rate
Glucose yeast extract peptone medium,
engineering of bacterial cells for
physiology orientation
[46]
Lactococcus lactis subsp. lactis
CV56
co-expression of gadC and
gadB
25.61 g/L
in a two-stage pH control batch
fermentation strategy
50 ◦C, pH 4.7 genetic engineering of
Escherichia coli cells [52]
L. brevis 9530: pNZ8148-gadBC
isozymes of glutamate
decarboxylase
104.38 ± 3.47 g/L
at 72 h fed-batch fermentation with
two-stage pH and temperature control
Overexpression of GAD isoforms of
GAD, gadA, and gadB [53]
L. delbrueckii subsp. Bulgaricus;








MSG 1.3 mg/mL, NaCl 2%,
amount of PLP:MSG 0.72:1.3, pH 6.5,
33 ◦C
[54]
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Table 2. Cont.
Microorganisms Employed
in Bioprocess Yield of GABA, or Product Requirements Reference
L. plantarum DSM19463
4.83 mM of GABA; grape beverage as a
functional drink; dermatological
application
grape must, addition of
18.4 mM L-glutamate, pH 6.0, 30 ◦C,
fermentation 72 h.
[57]
L. brevis NCL912 response
surface methodology
1005.81 ± 47.88 mM,
in 48 h fed-batch fermentation
30–35 ◦C, 5.0 and 250–500 mM
glutamate [58,59]
L. brevis RK03 62,523 mg/L,after 88 h
1% glucose; 2.5% yeast extract; 2 ppm




10 litre fermenter at 100 rpm
mixing
205.8 ± 8.0 g/L
after 48 h of fermentation
MSG replaced by glutamic acid
295 g/L glutamic acid, 25 g/L each
glucose and yeast extract; 25 mg/L
MnSO4·H2O; 2 g/L Tween-80; 32 ◦C
[61]
Studies have also suggested the use of selective culture cultivation systems for operat-
ing the process of biosynthesis, depending on type of microorganism/s being employed,
such as a batch, fed-batch, single-culture, or co-culture in liquid-submerged fermentation.
The effectiveness of solid-state fermentation system should be exploited, when employing
mycelial–fungal strains on solid substrates. Columns 2 and 3 in Table 2 include the details
of such factors and process requirements.
5. Conclusions
The information presented in the above sections has clearly identified the fast-growing
potential of GABA in health sector, due to its several pharmacological properties. There-
fore, with an increasing demand in the market, there is a need for establishing an effective
biosynthetic process for its availability at a lower cost. This review has summarized infor-
mation on specific microorganisms involved in GABA production, aiding understanding
of their requirements for essential factors needed in their growth cycle to achieve the
optimum synthesis GABA. Suitable methods could be used for optimizing the yield in
a cost-effective process. This is a concise overview only providing selected information
on the biosynthesis of this compound. Future studies can focus on improving production
by genetic manipulation to enable some of the strains to reduce the need to add the PLP
compound in the production medium. The target would be aimed at reducing the cost of
production of GABA on a large scale, through a microbiological route. The study of efficient
biocatalysts and their factors required in microbial synthesis of GABA will certainly help
to establish a yield-efficient, low-cost production process. This approach will ensure its
availability as a low-cost ingredient for application in food and pharmaceutical industries.
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